Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Princeton, NJ

6 abstracts

Abstract
Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).
Org: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Georgetown-Lombardi Comprehensive Cancer Center, Bristol Myers Squibb, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,
Abstract
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.
Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,
Abstract
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.
Org: Memorial Sloan Kettering Cancer Center, New York, NY, Institut Gustave Roussy, Villejuif, France, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan,
Abstract
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
Org: Bristol Myers Squibb, Princeton, NJ, Massachusetts General Hospital, Boston, MA, MD Anderson Cancer Center,
Abstract
How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question.
Org: Gilead Sciences, Inc., Foster City, CA, Certara, Inc., Princeton, NJ, Gilead Sciences Inc.,